Financial Performance - The company's operating revenue for Q3 2024 was ¥138,898,375.76, representing an increase of 18.32% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 reached ¥35,159,014.79, a significant increase of 140.02% year-over-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥34,533,527.63, up 144.80% from the previous year[3]. - Basic earnings per share for Q3 2024 was ¥0.31, reflecting a 138.46% increase compared to the same period last year[3]. - Total operating revenue for the first three quarters of 2024 reached ¥337,836,114.63, an increase of 15.99% compared to ¥291,226,325.99 in the same period of 2023[17]. - Net profit for the third quarter of 2024 was ¥56,816,007.20, compared to ¥34,796,237.25 in the same quarter of 2023, representing a year-over-year increase of 63.38%[18]. - Earnings per share for the third quarter of 2024 were ¥0.51, up from ¥0.31 in the same quarter of 2023, indicating a growth of 64.52%[19]. Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥1,528,053,413.91, marking a 16.14% increase from the end of the previous year[3]. - The company's total current assets as of September 30, 2024, amount to ¥651,410,473.70, an increase from ¥609,304,574.93 as of December 31, 2023[12]. - The company's total liabilities increased to ¥609,403,059.19 in Q3 2024 from ¥435,629,416.65 in Q3 2023, marking a rise of 39.87%[16]. - The total equity attributable to shareholders reached ¥918,613,672.65 in Q3 2024, compared to ¥879,928,271.27 in Q3 2023, an increase of 4.34%[16]. Research and Development - Research and development expenses for Q3 2024 totaled ¥5,295,750.49, a decrease of 48.37% year-over-year[3]. - The proportion of R&D expenses to operating revenue for Q3 2024 was 3.81%, down 4.93 percentage points from the previous year[3]. - Research and development expenses for the first three quarters of 2024 were ¥28,578,274.28, up from ¥20,381,012.27 in 2023, reflecting an increase of 40.25%[17]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥26,790,765.14, showing a decline of 13.43% compared to the same period last year[2]. - The cash inflow from operating activities was CNY 402,664,282.16, a decrease of 3.1% compared to CNY 418,642,923.47 in the same period of 2023[20]. - The cash outflow from operating activities totaled CNY 375,873,517.02, resulting in a net cash flow from operating activities of CNY 26,790,765.14, down from CNY 30,945,700.40 in 2023[22]. - The cash inflow from investment activities was CNY 280,858,713.32, compared to CNY 271,438,776.87 in the previous year, marking an increase of 3.2%[22]. - The cash outflow from investment activities was CNY 484,766,037.04, leading to a net cash flow from investment activities of -CNY 203,907,323.72, an improvement from -CNY 315,087,433.34 in 2023[22]. - The cash inflow from financing activities was CNY 180,081,522.50, while the cash outflow was CNY 74,528,134.63, resulting in a net cash flow from financing activities of CNY 105,553,387.87[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 5,005, with the top ten shareholders holding a combined 55.62% of shares[8]. - Sichuan Saino Investment Co., Ltd. holds 42,000,000 shares, accounting for 37.50% of total shares[10]. - The company has not reported any significant changes in shareholder relationships or agreements among the top shareholders[11]. Future Outlook - The company attributed the significant increase in net profit to the growth in sales of raw materials and formulations[6]. - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth prospects[17]. - The company has not disclosed any new strategies or product developments in the current report[12]. Tax and Other Financial Activities - The company received CNY 6,047,828.58 in tax refunds, an increase from CNY 5,283,569.05 in the same period last year[20]. - The company reported a significant increase in cash received from other operating activities, totaling CNY 76,175,140.47, compared to CNY 40,115,705.55 in 2023[20]. - The company paid CNY 24,245,694.77 in taxes, up from CNY 16,749,832.95 in the previous year[22]. Accounting Standards - The company has not adopted new accounting standards for the current year, as indicated in the report[24].
圣诺生物(688117) - 2024 Q3 - 季度财报